Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Secondary objectives: * To evaluate the efficacy of cenobamate tablets and suspension in pediatric subjects with partial onset (focal) seizures * To evaluate the pharmacokinetics of cenobamate tablets and suspension in pediatric subjects with partial onset seizures * To evaluate the PK/pharmacodynamics of cenobamate in pediatric subjects with partial onset (focal) seizures * Acceptability and palatability assessment (determined by a 5-point Hedonic Scale) of the oral formulation and the 12.5 mg tablets - Day 1, and Day 15